These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30758859)

  • 1. Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma.
    Kato J; Hida T; Someya M; Sato S; Sawada M; Horimoto K; Fujioka M; Minowa T; Matsui Y; Tsuchiya T; Kitagawa M; Nakata K; Sakata KI; Torigoe T; Uhara H
    J Dermatol; 2019 Apr; 46(4):328-333. PubMed ID: 30758859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA
    Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
    Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
    Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study.
    Mowery YM; Patel K; Chowdhary M; Rushing CN; Roy Choudhury K; Lowe JR; Olson AC; Wisdom AJ; Salama JK; Hanks BA; Khan MK; Salama AKS
    Radiother Oncol; 2019 Sep; 138():114-120. PubMed ID: 31252292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab.
    Nomura M; Otsuka A; Yoshimura M; Nonomura Y; Kaku Y; Matsumoto S; Muto M
    Cancer Chemother Pharmacol; 2018 May; 81(5):823-827. PubMed ID: 29502140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
    Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D
    Eur J Cancer; 2019 Sep; 119():168-178. PubMed ID: 31445199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
    Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
    Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
    Funck-Brentano E; Baghad B; Fort M; Aouidad I; Roger A; Beauchet A; Otmezguine Y; Blom A; Longvert C; Boru B; Saiag P
    Int J Cancer; 2020 Sep; 147(6):1707-1714. PubMed ID: 32083739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
    Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
    J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
    Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
    J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local and disease control for nasal melanoma treated with radiation and concomitant anti-programmed death 1 antibody.
    Hanaoka Y; Tanemura A; Takafuji M; Kiyohara E; Arase N; Suzuki O; Isohashi F; Ogawa K; Fujimoto M
    J Dermatol; 2020 Apr; 47(4):423-425. PubMed ID: 32030784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma.
    Ohashi H; Takeuchi S; Miyagaki T; Kadono T
    Drug Discov Ther; 2020 Jul; 14(3):117-121. PubMed ID: 32595179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy.
    Iga N; Otsuka A; Hirata M; Kataoka TR; Irie H; Nakashima C; Matsushita S; Uchi H; Yamamoto Y; Funakoshi T; Fujisawa Y; Yoshino K; Fujimura T; Hata H; Ishida Y; Kabashima K
    Cancer Sci; 2019 Nov; 110(11):3434-3441. PubMed ID: 31509303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016.
    Taquin H; Fontas E; Massol O; Chevallier P; Balloti R; Beranger G; Lacour JP; Passeron T; Montaudié H
    Ann Dermatol Venereol; 2018 Nov; 145(11):649-658. PubMed ID: 30098818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are we over-treating with checkpoint inhibitors?
    Danson S; Hook J; Marshall H; Smith A; Bell S; Rodwell S; Corrie P
    Br J Cancer; 2019 Oct; 121(8):629-630. PubMed ID: 31527686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.
    Sundahl N; Seremet T; Van Dorpe J; Neyns B; Ferdinande L; Meireson A; Brochez L; Kruse V; Ost P
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):828-835. PubMed ID: 30951807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
    Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
    Parakh S; Park JJ; Mendis S; Rai R; Xu W; Lo S; Drummond M; Rowe C; Wong A; McArthur G; Haydon A; Andrews MC; Cebon J; Guminski A; Kefford RF; Long GV; Menzies AM; Klein O; Carlino MS
    Br J Cancer; 2017 Jun; 116(12):1558-1563. PubMed ID: 28524161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.